The biopharmaceutical problems begin with the molecule itself. Tamoxifen is a synthetic nonsteroidal selective estrogen receptor modulator, classified as a Biopharmaceutical Classification System Class II drug, meaning low solubility combined with high permeability makes dissolution the rate-limiting step for absorption. Its log P value sits between six and seven, confirming extreme lipophilicity, while a tertiary amine group with a pKa of roughly 8.8 to 9.0 gives it pH-dependent solubility behavior. Its intrinsic aqueous solubility measures approximately 1.60 × 10⁻² mM. Even the clinically used citrate salt, which improves solubility relative to the free base, cannot fully escape dissolution-limited bioavailability. A stable crystal lattice further reduces thermodynamic solubility compared with amorphous forms, and conventional fixes such as micronization or salt modification often prove insufficient to optimize both solubility and release control.

Compounding these physicochemical headaches is a pharmacogenetic one. Tamoxifen’s most potent active metabolites, endoxifen and 4-hydroxytamoxifen, are formed through hepatic biotransformation that depends substantially on CYP2D6 activity, which partially explains why patients respond so differently to identical doses. The review is explicit on this point: nanoformulation should not be regarded as a strategy that inherently bypasses CYP2D6-dependent metabolic activation. Tamoxifen itself retains antiestrogenic and antiproliferative activity, so enhanced cellular uptake and intracellular exposure to the parent drug may themselves contribute to the increased antiproliferative effects observed in laboratory studies. Prolonged therapy also carries risks, including endometrial carcinoma and thromboembolic complications, making any delivery innovation subject to a careful benefit-risk assessment.

Nanotechnology offers several mechanisms that directly address these constraints. Reducing particle size to the nanoscale increases specific surface area and thins the diffusion layer, accelerating dissolution according to the Noyes-Whitney equation, while increased particle curvature can raise saturation solubility through the Kelvin effect. Controlled release becomes possible by tuning carrier characteristics such as molecular weight, degree of crystallinity, hydrophilic-lipophilic balance, and cross-linking density; in polymer nanoparticles, release typically reflects a combination of diffusion and matrix erosion. Tumor accumulation can occur passively through the enhanced permeability and retention effect, exploiting disrupted tumor vasculature and poor lymphatic drainage, and actively through surface ligands such as antibodies, peptides, sugars, or vitamins that bind receptors overexpressed on cancer cells. Encapsulation can also prolong circulation time, reduce premature biotransformation, and enable theranostic functions that combine therapy with real-time diagnostic monitoring.

Chitosan enters this picture as an unusual candidate. It is a linear cationic polysaccharide obtained by deacetylating chitin, the structural biopolymer found in crustacean exoskeletons, insects, and fungal cell walls, with industrial production typically drawing on waste from fish processing. Its backbone consists of β-(1→4)-linked D-glucosamine and N-acetyl-D-glucosamine units, and the ratio between them, described by the degree of deacetylation, drives significant heterogeneity in commercial and laboratory forms. Primary amino groups at the C-2 position become protonated at acidic pH, giving chitosan its unique cationic character among natural polysaccharides and explaining its pH-dependent solubility in weak organic acids. This feature underlies mucoadhesion, electrostatic interactions with biological membranes, and the ability to form polymer complexes and nanostructures, while the reactive amine and hydroxyl groups make it exceptionally flexible for chemical modification.

Native chitosan, however, carries real limitations for a drug like tamoxifen. Its solubility is limited and highly pH-dependent, so deprotonation under neutral and slightly alkaline conditions leads to aggregation and unpredictable release. Batch-to-batch variability in molecular weight and degree of deacetylation complicates standardization and regulatory evaluation. Non-functionalized chitosan offers limited control over drug loading, and in the absence of specific polymer-drug interactions, pronounced burst release is common. Upon systemic administration, nonspecific electrostatic interactions with plasma proteins and cell membranes can trigger rapid clearance or off-target accumulation. Most critically for tamoxifen, the predominantly hydrophilic polymer lacks distinct hydrophobic domains, so lipophilic drugs distribute unevenly within the matrix, yielding lower encapsulation efficiency and less stable delivery systems.

Chemical modification changes this calculus dramatically. In one widely cited study, researchers covalently conjugated chitosan with stearic acid to form an amphiphilic copolymer capable of self-assembling into polymeric micelles. Confirmed by FT-IR and NMR spectroscopy, the system demonstrated increased tamoxifen loading, controlled release, and significantly enhanced cytotoxicity against MCF-7 breast cancer cells compared with the free drug. In vivo pharmacokinetic studies showed a significant increase in the area under the concentration-time curve, prolonged half-life, and reduced clearance. Encapsulation efficiency exceeded 90 percent, attributed to hydrophobic interactions between stearic acid chains and the drug, supplemented by hydrogen bonds and van der Waals forces that retain the active substance within the micellar structure.

Graft polymerization offers a second powerful strategy. Chitosan-modified PLGA micelles containing tamoxifen achieved an entrapment efficiency of 89.78 ± 7.31 percent and a drug loading of 45 ± 4.24 percent, quantitative evidence that covalent hybrid modification improves tamoxifen incorporation. The same system exhibited a lower IC₅₀ than free drug and higher dermokinetic parameters in epidermis and dermis. Oleic acid-grafted carboxymethylated chitosan demonstrates that combining hydrophilic and hydrophobic functionalization produces amphiphilic micellar systems suited to hydrophobic antitumor agents. Recent Quality by Design work on polycaprolactone-chitosan hybrid nanocomposites yielded an optimized tamoxifen formulation with roughly 47 percent entrapment efficiency and a biphasic release profile, though biological evaluation remained limited to in vitro models against MCF-7 and 4T1 cells.

Surface engineering provides an alternative that leaves the chitosan backbone untouched. A direct comparison between uncoated and alginate-coated chitosan nanoparticles revealed that alginate increases particle size and flips surface charge from positive to negative while generally reducing encapsulation efficiency. The trade-off comes in release control: initial tamoxifen release under acidic conditions dropped from approximately 10 to 18 percent for uncoated nanoparticles to just 2 to 3 percent after alginate coating, followed by a more controlled pH-dependent profile. This suggests the alginate layer is particularly advantageous for oral administration, where protecting the carrier in the gastric environment and releasing drug in the intestine are desirable. In a separate hybrid approach, tamoxifen was completely released from unmodified porous silicon within six hours, whereas a chitosan/silica xerogel coating prolonged complete release to approximately seven days, showing that complementary material properties within a delivery architecture can provide substantially greater control than individual components.

Production method matters as much as chemistry. Ionotropic gelation, based on electrostatic interactions between protonated chitosan and multivalent anions such as tripolyphosphate, is simple and organic-solvent-free but often yields lower encapsulation efficiency for highly lipophilic molecules like tamoxifen. Particle size depends on chitosan concentration, molecular weight, TPP levels, pH, and mixing speed, with more vigorous blending producing smaller particles through rapid nucleus formation and limited aggregation. Self-assembly of amphiphilic derivatives forms micelle-like structures whose properties depend on degree of modification, concentration, and environmental conditions. Emulsion techniques, nanospray drying, and polyelectrolyte complexation with anionic polymers such as gellan gum round out the toolkit, with the latter producing biocompatible nanocapsules that showed increased cytotoxicity against MCF-7 cells compared with free drug.

Release kinetics from these systems typically follows a biphasic profile: an initial burst from surface-localized drug, then sustained diffusion-controlled release describable by Higuchi and Korsmeyer-Peppas models. The Korsmeyer-Peppas exponent n distinguishes Fickian diffusion from non-Fickian transport, and non-Fickian behavior is frequently observed in amphiphilic chitosan systems, reflecting combined diffusion and polymer relaxation. Modified derivatives with increased hydrophobicity show stronger drug retention, reducing burst release by stabilizing lipophilic molecules within hydrophobic cores. PEGylation of chitosan can prolong circulation and reduce recognition by the reticuloendothelial system, though the strategy carries the accelerated blood clearance effect from anti-PEG antibodies and the so-called PEG dilemma, where the hydrophilic coating limits cellular uptake and intracellular delivery.

In vitro evidence consistently shows that chitosan-based nanoparticles improve cellular uptake and antiproliferative effect, with increased cytotoxicity in MCF-7 lines attributed to greater intracellular accumulation. In vivo, polymeric nanocarriers appear to improve tissue distribution and tumor exposure. Combining tamoxifen with phloretin-loaded chitosan nanoparticles in DMBA-induced breast cancer mouse models produced synergistic anti-inflammatory and antiproliferative effects, including reductions in IL-6 and cyclin D1, improved histopathology, and increased tumor-cell apoptosis, though the specific contribution of the chitosan carrier itself was not isolated against blank nanoparticles. Hyaluronic acid-coated chitosan nanoparticles achieved 55 percent encapsulation efficiency for tamoxifen, adding another targeting dimension.

The review’s most sobering conclusion concerns the evidence base itself. Hydrophobic and amphiphilic modifications, particularly fatty acid-conjugated and graft-polymer systems, currently provide the most direct experimental support, while carboxymethylated, thiolated, and PEGylated derivatives are supported predominantly by studies with other hydrophobic drugs. Differences in nanoparticle composition, preparation methods, drug-to-polymer ratios, release conditions, and biological models preclude reliable quantitative comparison across studies, so apparent superiority of any strategy cannot yet be established. A gap also separates formulation optimization from clinical trials, since physicochemical advantages do not necessarily translate into improved therapeutic efficacy. Future work must systematically evaluate cellular uptake, pharmacokinetics, biodistribution, tumor accumulation, and antitumor efficacy in vivo, establishing rational structure-performance relationships. Modified chitosan nanocarriers represent a promising but underexplored platform for tamoxifen, and their development requires coordinated efforts across pharmaceutical technology, nanomedicine, and clinical pharmacology.

Subject of Research: Technological approaches to tamoxifen nanoformulation: emphasis on modified chitosan-based nanoparticles: a review

Article Title: Technological approaches to tamoxifen nanoformulation: emphasis on modified chitosan-based nanoparticles: a review

Article References: Argilashki, D. (2026). Technological approaches to tamoxifen nanoformulation: emphasis on modified chitosan-based nanoparticles: a review. Pharmacia, 73, Article e206326. https://doi.org/10.3897/pharmacia.73.e206326

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e206326

Keywords: Technological, approaches, tamoxifen, nanoformulation, emphasis, modified, chitosan-based, nanoparticles, review, scientific research

The research, conducted by a team at the University of Health Sciences Prof. Dr. Cemil Tascioglu City Hospital and published in BMC Cancer, examined 138 premenopausal women with non-metastatic, hormone receptor-positive, HER2-positive breast cancer. All of the patients had undergone neoadjuvant therapy — treatment given before surgery — built around anti-HER2 agents, followed by surgical removal of their tumors between 2015 and 2024. The investigators then split the cohort according to whether the women received ovarian function suppression, or OFS, during the adjuvant period, the phase of care that follows surgery and is designed to mop up any remaining cancer cells.

The biology behind the question is straightforward. In premenopausal women, the ovaries are the dominant source of estrogen, the hormone that fuels the growth of hormone receptor-positive tumors. Blocking ovarian output — typically with gonadotropin-releasing hormone agonists that effectively switch the ovaries off — dramatically lowers circulating estrogen. Combined with drugs such as tamoxifen, which blocks estrogen receptors on cancer cells, or aromatase inhibitors, which block estrogen synthesis in peripheral tissues, ovarian suppression is intended to starve any residual disease of its principal growth signal. In HER2-negative disease, landmark trials have shown clear benefits from this strategy. But HER2-positive tumors behave differently, and the arrival of potent anti-HER2 therapies such as trastuzumab has transformed outcomes, raising the possibility that the incremental value of ovarian suppression has shrunk.

That possibility is precisely what the Turkish team set out to test. Of the 138 patients, 60 — or 43.5 percent — received ovarian function suppression as part of their adjuvant endocrine treatment. The remaining 78 did not. The researchers tracked three primary endpoints: disease-free survival, which measures the time before cancer returns anywhere in the body; distant disease-free survival, which focuses specifically on spread to distant organs; and overall survival. They also assessed pathological complete response, abbreviated pCR, as a secondary endpoint. A pCR means that when pathologists examine the tissue removed at surgery, they find no invasive cancer in the breast and no cancer in the sampled lymph nodes — a marker widely regarded as one of the strongest predictors of long-term cure.

The headline numbers were striking in places. Overall, 42 percent of the entire cohort achieved a pathological complete response, a figure that underscores just how powerful neoadjuvant anti-HER2 therapy has become. After a median follow-up of 56 months, 20 patients — 14.5 percent — had experienced a recurrence or developed metastatic disease, and 11 patients, or 8 percent, had died. Those figures, sobering as they are, reflect the reality of a disease subtype that remains challenging even in the modern therapeutic era.

When the investigators compared the two groups, the differences were modest at best. Five-year overall survival was 93.9 percent among women who received ovarian suppression versus 85.8 percent among those who did not — a numerical gap, but one that did not reach statistical significance, with a p-value of 0.4. Disease-free survival was essentially identical between the arms: 80.7 percent with ovarian suppression and 81.3 percent without, yielding a p-value of 0.9. Distant disease-free survival followed the same pattern. In other words, on the primary measures of whether cancer came back or whether patients lived, the addition of ovarian suppression made no statistically detectable difference in this cohort.

The most intriguing signal emerged when the researchers stratified patients by their response to neoadjuvant therapy. Women who achieved a pathological complete response had excellent outcomes regardless of whether their ovaries were subsequently suppressed — their five-year overall survival was a remarkable 100 percent. This finding reinforces a growing consensus in oncology: for patients whose tumors vanish under preoperative anti-HER2 treatment, the prognosis is already so favorable that additional endocrine intensification may contribute little. The residual-disease group told a more nuanced story. Among women who still had detectable cancer at surgery, ovarian suppression was associated with numerically higher overall survival — 89.9 percent versus 77.6 percent — but this apparent advantage did not translate into a disease-free survival benefit, and the difference was not statistically significant.

To account for the possibility that the two groups differed in ways that could confound the comparison — differences in tumor size, nodal involvement, grade, or the type of endocrine therapy received — the team performed multivariate analysis, a statistical technique that adjusts for multiple variables simultaneously. The result was unambiguous: ovarian function suppression showed no independent association with disease-free survival, distant disease-free survival, or overall survival once other factors were taken into account. The authors are careful to note, however, that the study’s statistical power was limited. With 138 patients and relatively few events — 20 recurrences and 11 deaths — the analysis simply cannot exclude a modest benefit that a larger trial might detect.

Another critical caveat concerns the composition of the endocrine therapy itself. The cohort was predominantly treated with tamoxifen, the selective estrogen receptor modulator that has long been the backbone of adjuvant therapy in premenopausal women. Whether ovarian suppression paired with aromatase inhibitors — a more aggressive regimen that eliminates nearly all estrogen production — would perform differently cannot be answered by this dataset. The authors explicitly caution that, given the limited statistical power and the tamoxifen-dominated treatment landscape, their findings should be interpreted with care, and they call for prospective studies to define the role of ovarian suppression in this population with the rigor that only randomized designs can provide.

For clinicians and patients, the practical message is one of individualized decision-making rather than a blanket rule. Ovarian suppression is not a free intervention: it induces a premature, often abrupt menopause, bringing hot flashes, bone density loss, sexual dysfunction, and potential effects on fertility and quality of life. If a young woman achieves a pathological complete response after neoadjuvant anti-HER2 therapy, the data suggest her prognosis is excellent without intensification, and she and her physician may reasonably weigh the burden of suppression against its uncertain benefit. For those with residual disease, the numerically better overall survival observed with suppression — though not statistically significant — may still inform a shared decision, particularly for patients with other high-risk features. What this single-center experience ultimately demonstrates is that the era of effective anti-HER2 therapy has changed the calculus of endocrine intensification, and that the questions guiding treatment for premenopausal, hormone receptor-positive, HER2-positive breast cancer are now as much about avoiding overtreatment as about maximizing it. Larger, prospective trials will be needed to settle the matter definitively, but for now, this study offers a data-driven reminder that more intensive therapy is not always better therapy.

Subject of Research: Ovarian function suppression in adjuvant endocrine therapy for premenopausal hormone receptor-positive, HER2-positive breast cancer after neoadjuvant anti-HER2 therapy

Article Title: The effect of adding ovarian function suppression to adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive, HER2-positive breast cancer who have undergone neoadjuvant therapy: a single-center experience

Article References: Aydin, O., Dogan, H. G. Y., Sonusen, S. D., Erciyestepe, M., Ozturk, A. E., Buyukkuscu, A., Isleyen, Z. S., & Erturk, K. (2026). The effect of adding ovarian function suppression to adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive, HER2-positive breast cancer who have undergone neoadjuvant therapy: a single-center experience. BMC Cancer, 26(1), Article 1140. https://doi.org/10.1186/s12885-026-17017-8

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17017-8

Keywords: breast cancer, HER2-positive, hormone receptor-positive, ovarian function suppression, neoadjuvant therapy, adjuvant endocrine therapy, pathological complete response, disease-free survival, overall survival, tamoxifen, premenopausal, oncology

The research team, led by Olivia M. Shorthouse and Juan F. Quintana, set out to answer a deceptively simple question. Reproductive dysfunction has been reported anecdotally in both human patients and experimental animals infected with T. brucei, but nobody knew whether the parasites actually entered the female reproductive tract or whether the observed problems were merely secondary effects of systemic illness. By tracking parasite localisation during both acute and chronic stages of infection in mice, the investigators demonstrated that the organisms take up residence in the endometrium, the specialised mucosal lining of the uterus. This direct infiltration of reproductive tissue places the parasite in intimate contact with the immune cells and hormone-responsive epithelium that govern fertility.

What the parasites do once they arrive proved to be as important as where they settle. The study revealed a progressive and multi-layered deterioration of reproductive health as infection moved from its acute phase into chronicity. Chronically infected mice lost substantial fat mass, a sign of the metabolic wasting characteristic of trypanosome disease. Their oestrous cycles, the rodent equivalent of the menstrual cycle, became disrupted and eventually arrested. The uterus and ovaries themselves shrank, showing measurable atrophy. Perhaps most strikingly, the researchers documented extensive transcriptional dysregulation across the hypothalamic-pituitary-gonadal axis, the hormonal control circuit that links the brain to the gonads and orchestrates fertility from the top down.

The hypothalamic-pituitary-gonadal axis is a delicate three-tiered system. The hypothalamus, a small region at the base of the brain, releases gonadotropin-releasing hormone in pulses that instruct the pituitary gland to secrete luteinising hormone and follicle-stimulating hormone. These hormones, in turn, act on the ovaries to drive follicle development, ovulation, and the production of oestrogen and progesterone. The new findings show that chronic T. brucei infection distorts gene expression at every level of this hierarchy, implying that the parasite does not merely damage the uterus locally but interferes with the central neuroendocrine commands that regulate it. This systemic rewiring of reproductive control represents a form of pathology that has rarely been characterised in parasitic infection.

Immune remodelling within the uterus emerged as a central feature of the disease process. In both acute and chronic infection, the researchers observed infiltration of T cells into uterine tissue and activation of pro-inflammatory myeloid cells, the innate immune population that includes monocytes, macrophages, and their inflammatory descendants. Beyond the uterus itself, the team detected broader type 1 inflammatory signatures spreading across reproductive tissues and components of the hypothalamic-pituitary-gonadal axis. Type 1 inflammation, typically driven by interferon signalling and associated with defence against intracellular pathogens, is not normally the dominant immune tone of the reproductive tract, which tends to favour tolerance and controlled responses. Its expansion here suggests that the infection fundamentally reprograms the immunological identity of the female reproductive organs.

The ovaries told their own story of damage. Examination of ovarian pathology revealed follicular degeneration, meaning the structures that house and nurture developing eggs were deteriorating. The researchers also counted a reduction in corpora lutea, the transient endocrine structures that form after ovulation and produce the progesterone needed to support early pregnancy. Fewer corpora lutea indicate fewer successful ovulations, a direct readout of impaired fertility. Alongside these structural changes, alterations to steroidogenic pathways were detected, pointing to disruption of the enzymatic machinery that converts cholesterol into the steroid hormones essential for cyclicity and reproduction.

One of the most compelling experiments in the study involved a therapeutic intervention designed to disentangle two competing explanations. If the uterine damage were driven purely by falling oestrogen levels, then restoring oestrogen signalling should rescue the tissue. The researchers treated infected mice with tamoxifen, a selective oestrogen receptor modulator widely known for its use in breast cancer therapy. The results were revealing but partial. Tamoxifen restored uterine morphology and prevented the arrest of the oestrous cycle, demonstrating that endocrine dysfunction is indeed a major driver of the structural collapse of the uterus. However, the hormone treatment did not reverse the infection-induced remodelling of the uterine immune environment. The inflammatory cell populations and their activation states persisted despite hormonal rescue.

This dissociation carries a significant conceptual message: endocrine dysfunction and infection-driven inflammation are two distinct processes, each contributing to reproductive pathology through separate routes. Hormonal collapse explains the loss of normal uterine architecture and cyclicity, but the immune reprogramming is a direct consequence of the infection itself and cannot be corrected simply by fixing the hormonal signal. For patients, this implies that treating the hormonal consequences of chronic parasitic disease may not be sufficient to restore full reproductive health unless the underlying inflammatory drive, and ideally the infection itself, is also addressed. It also raises the possibility that immune-mediated damage to the reproductive tract could outlast or operate independently of the visible endocrine symptoms.

The broader significance of the work lies in what it says about systemic infection as a whole. The female reproductive tract is an immunologically dynamic organ that must balance defence against pathogens with the tolerance required for successful reproduction. The new findings identify it as a major target of T. brucei infection and demonstrate how a chronic parasitic disease can disrupt reproductive physiology through a combination of immune, endocrine, and metabolic pathways acting in parallel. Fat wasting, hypothalamic dysregulation, ovarian degeneration, and uterine inflammation are not isolated phenomena but interconnected consequences of a systemic infection that reaches into every tier of reproductive control. The authors suggest that this interplay between metabolism, immunity, and endocrinology may be relevant well beyond trypanosomiasis.

Indeed, the study closes with a methodological warning for the wider research community. Because the female reproductive tract has been so frequently overlooked in models of systemic inflammation, the effects of other infectious and inflammatory diseases on fertility and reproductive endocrinology may be underappreciated. The researchers argue that future studies of systemic inflammatory conditions should specifically assess the female reproductive tract rather than assuming it is a passive bystander. For sleeping sickness, a disease that affects tens of thousands of people in sub-Saharan Africa, the findings open a new dimension of clinical concern and a new set of questions about how parasitic infection shapes long-term reproductive health in survivors. They also provide a framework for investigating whether other chronic infections quietly inflict similar damage on the reproductive system.

Subject of Research: Trypanosoma brucei infection of the female reproductive tract and its effects on uterine immunity and reproductive hormone regulation

Article Title: Trypanosoma brucei infection remodels the uterine immune environment and drives neuroendocrine dysfunction

Article References: Shorthouse, O. M., Barnes, C., Colombo, S. A. P., Costa, J., Wonsbek, K., Mohon, A., MacDonald, A. S., Mann, E., Costain, A. H., & Quintana, J. F. (2026). Trypanosoma brucei infection remodels the uterine immune environment and drives neuroendocrine dysfunction. PLOS Pathogens, 22(10), e1014667. https://doi.org/10.1371/journal.ppat.1014667

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014667

Keywords: Trypanosoma brucei, sleeping sickness, uterus, endometrium, reproductive immunology, hypothalamic-pituitary-gonadal axis, oestrous cycle, ovarian pathology, tamoxifen, inflammation, parasitology, PLOS Pathogens

The motivation behind miRDrug stems from a well-known problem in pharmaceutical research: identifying new therapeutic targets is extraordinarily expensive, and wet-lab experiments to uncover microRNA-drug relationships are slow, complex and resource-intensive. Computational approaches offer a cost-effective alternative, but most existing tools examine only a single slice of the picture, such as microRNA-disease or gene-pathway associations. The authors argue that this fragmentation impedes a comprehensive understanding of how microRNA expression shapes drug response. Their solution is to integrate prior biological knowledge directly into the machine-learning pipeline, so that the algorithm does not just crunch numbers but reasons over curated biological facts.

At the heart of miRDrug is the Grouping-Scoring-Modeling approach, or G-S-M, a framework previously developed by Yousef and colleagues and already deployed in tools such as GediNET, miRGediNET, maTE and PriPath. The strategy is elegant in its simplicity. First, features, in this case genes, are grouped according to external biological knowledge rather than left as thousands of individual columns of expression data. Second, each group is scored for how well it discriminates between two classes of samples, such as patients and healthy controls. Third, the top-ranked groups are fed into a machine-learning classifier, here a Random Forest, to build a predictive model. What sets miRDrug apart is a new component the authors call 3BPK, for Three Biological Prior Knowledge, which fuses information from miRTarBase version 9.0, the ncRNADrug database version 1.0 and the Drug-Gene Interaction Database DGIdb version 5.0.

The 3BPK module works by pairing microRNAs with drugs using the ncRNADrug database, then retrieving the target genes of each microRNA from miRTarBase and the associated genes of each drug from DGIdb. For every microRNA-drug pair, the tool computes the intersection of the two gene sets, producing a group of genes that are simultaneously linked to the microRNA and the drug. In total, the integrated databases supply 2,599 microRNAs connected to 15,064 genes through 502,652 interactions, 23,268 drugs linked to 3,899 genes through 81,129 interactions, and 17,372 microRNA-drug relationships covering 2,550 microRNAs and 326 drugs. From these resources, the researchers constructed 14,725 unique microRNA-drug pairs, each with its own shared-gene group and a Jaccard-style similarity score quantifying the overlap between the two gene sets.

The resulting overlap statistics reveal how sparse, yet meaningful, these connections can be. Some pairs, such as the microRNA hsa-let-7a-2-3p with the chemotherapy drug oxaliplatin, share no genes at all, yielding a similarity score of zero. Others show richer intersections: hsa-let-7a-5p paired with doxorubicin shares seven genes including bcl2, ccnd1 and casp3, while hsa-mir-26b-5p paired with cisplatin shares 27 genes, among them well-known cancer genes such as brca1, rb1 and myc. A histogram of the distribution shows a strongly right-skewed pattern, with 5,021 of the pairs having no common genes and progressively fewer pairs sharing larger numbers. The authors emphasize that an overlap does not imply direct molecular interaction; rather, it suggests shared pathways or biological relevance that could guide future experiments.

To test whether these biologically defined gene groups carry real predictive signal, the team applied miRDrug to ten human gene expression datasets from the Gene Expression Omnibus, spanning diseases from glioma and prostate cancer to lung adenocarcinoma, leukemia, pulmonary hypertension, colorectal cancer and colitis. Each dataset was evaluated with 100 repeated stratified train-test splits, using 90 percent of samples for training and 10 percent for held-out testing, with an inner five-fold cross-validation used to score candidate groups. The results were striking in several cases. On the GDS4516_4718 colorectal cancer dataset, miRDrug achieved an area under the curve of 0.999 with an accuracy of 0.994 using only about 5.6 genes from its top two ranked groups. The glioma dataset GDS1962 reached an AUC of 0.944, and the lung adenocarcinoma dataset GDS3257 hit 0.979. Performance was weaker on the pediatric acute lymphoblastic leukemia relapse dataset GDS4206, which the authors attribute to the high biological heterogeneity of relapsed cancers and the limits of a two-class classification framework.

Importantly, the tool does more than classify. Using the RobustRankAggreg method with Benjamini-Hochberg false discovery rate correction, miRDrug prioritizes which microRNA-drug groups and which individual genes are most statistically reliable in a given disease context. In the prostate cancer dataset GDS2545, the top-ranked groups included hsa-miR-26b-5p paired with docetaxel and paclitaxel, carrying genes such as PTEN, FGFR3, GSTP1 and ABCG2, all plausibly tied to drug response and tumor biology. In the lung cancer dataset GDS3837, prioritized genes included NT5E, EGFR, ERBB2, ABCC3 and BDNF, each associated with cancer signaling or drug response. A comparison against a conventional Random Forest trained on all 12,558 retained features of the prostate dataset showed that the all-feature baseline achieved a slightly higher AUC of 0.849 versus 0.818, but miRDrug matched its accuracy of roughly 0.76 while using only about 16 genes, and, crucially, produced interpretable biological outputs that the black-box baseline cannot offer.

The most compelling case study came from breast cancer. Applying miRDrug to The Cancer Genome Atlas breast invasive carcinoma cohort, the researchers classified the Luminal A/B molecular subtypes against the HER2-enriched and basal-like subtypes, achieving a remarkable AUC of 0.99 with just 7.5 genes in the top-ranked group. That top group was the pairing of hsa-miR-29b-3p with tamoxifen, the widely used selective estrogen receptor modulator, sharing the genes ESR1, TGFB1, CCNA2 and NCOA3. The biological logic is coherent: ESR1 encodes the estrogen receptor alpha that drives many breast cancers, TGFB1 regulates proliferation and epithelial-to-mesenchymal transition, CCNA2 controls the cell cycle, and NCOA3 is a transcriptional coactivator implicated in tumor progression. Prior literature links the miR-29 family to tumor suppression and to tamoxifen sensitivity, and studies suggest that modulating miR-29b-3p levels could restore hormone-therapy responsiveness in resistant cells. Other top-ranked microRNAs in the breast cancer analysis, including miR-193b-3p, miR-302b-3p and miR-222-3p, likewise align with known roles in tumor suppression or progression.

The authors are candid about the limitations. The system depends on curated databases that may be incomplete or biased toward well-studied genes, meaning novel interactions could be missed. The pipeline is sensitive to noise in heterogeneous clinical data, and the scoring and ranking stages introduce computational overhead as dataset size grows. Most importantly, the findings remain computational prioritizations rather than experimentally validated mechanisms; the team plans in vitro studies to test high-confidence predictions. Even so, miRDrug represents a meaningful step toward integrative, knowledge-guided bioinformatics. By fusing three complementary databases into a single grouping-scoring-modeling pipeline, it offers researchers a systematic way to generate hypotheses about microRNA-drug-gene triads, particularly in the context of drug resistance, and moves the field closer to the personalized-medicine goal of tailoring therapies to the regulatory genetics of each patient’s tumor. The workflow is publicly available on GitHub, allowing other groups to reproduce the analyses and extend the approach to new datasets and disease contexts.

Subject of Research: A computational tool integrating microRNA, drug and gene interaction databases to study drug resistance mechanisms

Article Title: miRDrug: Comprehensive analysis of the shared genes within miRNA-drug pairs using grouping, scoring, and modeling approach

Article References: Qumsiyeh, E., Bakir-Gungor, B., & Yousef, M. (2026). miRDrug: Comprehensive analysis of the shared genes within miRNA-drug pairs using grouping, scoring, and modeling approach. Heliyon, 12(15), Article e45548. https://doi.org/10.1016/j.heliyon.2026.e45548

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45548

Keywords: microRNA, drug resistance, machine learning, bioinformatics, cancer, gene expression, tamoxifen, miR-29, Random Forest, database integration, personalized medicine, G-S-M approach

The research team, led by Arun Kumar Trivedi of the Division of Cancer Biology at CSIR-CDRI, with Samradhi Singh and Swati Srivastava as co-first authors, approached the question with an unbiased lens. Rather than testing a predetermined molecular pathway, they first treated the aggressive triple-negative breast cancer cell line MDA-MB-231 with ormeloxifene and then ran the protein contents of those cells through two-dimensional gel electrophoresis, a classic but powerful proteomic technique that separates proteins first by their electrical charge and then by their molecular weight. Differentially regulated protein spots were subsequently identified by MALDI-TOF/TOF mass spectrometry, allowing the team to build a catalog of the molecular players whose abundance shifted in response to the drug.

What emerged from that catalog was strikingly coherent. When the researchers performed functional categorization and pathway-level integration of the differentially regulated proteins, the changes did not scatter across unrelated cellular processes. Instead, they converged on a coordinated cellular response characteristic of stress-induced cellular senescence, the programmed state of stable cell-cycle arrest that healthy tissues use to quarantine damaged or potentially malignant cells. In other words, the proteome of the treated cells was telling a consistent story: ormeloxifene was not merely poisoning the cells or slowing them down temporarily, it was reprogramming them toward a senescent identity.

To confirm that impression, the team deployed a battery of complementary assays. MTT viability tests showed that ormeloxifene inhibited the growth of both MCF7 cells, an estrogen receptor-positive breast cancer line, and the triple-negative MDA-MB-231 line, with half-maximal inhibitory concentrations ranging from 7 to 9 micromolar. Colony formation assays demonstrated that the drug sharply reduced the ability of surviving cells to establish new colonies, with a notably stronger effect in MCF7 cells. Flow cytometric cell-cycle analysis then revealed the mechanistic core of the growth arrest: in MCF7 cells, ormeloxifene induced a G0/G1 arrest by decreasing the levels of CDK4 and CDK6, the cyclin-dependent kinases that normally drive cells through the restriction point of the cell cycle, while simultaneously increasing the CDK inhibitors p21Cip1 and p27Kip1, the molecular brakes that clamp down on those kinases.

The senescence evidence itself came from two independent histochemical stains. Senescence-associated beta-galactosidase staining, the traditional workhorse marker of senescent cells, showed a time-dependent increase in staining after ormeloxifene treatment. Sudan Black B staining, a more recently validated method that detects lipofuscin, the oxidized pigment granules that accumulate specifically in senescent cells, corroborated the result. Critically, the team also observed increased expression of established senescence markers by immunoblotting, and they describe the senescence as irreversible, meaning the cells did not resume proliferation even after prolonged exposure. That irreversibility matters enormously in cancer biology, because a reversible arrest can be escaped by tumor evolution, whereas a permanent one cannot.

Perhaps the most clinically tantalizing result, however, came from a combination experiment. The researchers found that ormeloxifene enhanced the sensitivity of MCF7 cells to tamoxifen, the gold-standard endocrine therapy for estrogen receptor-positive breast cancer that has been in use since the 1970s. Tamoxifen resistance remains one of the most stubborn problems in breast oncology, and any agent that can resensitize tumors to the drug would be of immediate translational interest. The authors suggest that the combination of ormeloxifene and tamoxifen may represent a potential therapeutic strategy for tamoxifen-resistant breast tumors, a hypothesis that will now need to be tested in more sophisticated models and, eventually, in patients.

The safety profile argument for repurposing ormeloxifene is unusually strong. The drug acts as a selective estrogen receptor modulator with mild estrogenic activity in bone and anti-estrogenic activity in uterine and breast tissue, a tissue-selective profile that mirrors the pharmacology of drugs like raloxifene. It has been used as a reversible, non-hormonal, once-weekly oral contraceptive in India for decades, and a phase II study published as far back as 1989 by Misra and colleagues evaluated centchroman as a non-steroidal anti-cancer agent in advanced breast cancer. Subsequent laboratory work has shown antiproliferative effects in head and neck cancer through modulation of the PI3K/mTOR pathway, efficient inhibition of ovarian cancer growth, suppression of desmoplasia and enhancement of gemcitabine sensitivity in pancreatic cancer, and G0/G1 arrest with ERK-mediated apoptosis in chronic myeloid leukemia cells. The new study adds senescence induction to this growing mechanistic portfolio.

Senescence as an anticancer mechanism has a complicated history. On one hand, inducing senescent cells in a tumor is a validated therapeutic concept, and chemotherapy itself frequently works partly by triggering senescence. On the other hand, senescent cells are not inert: they can secrete inflammatory and growth-promoting factors, and chemotherapy-induced senescence has been described as an adaptive mechanism that can drive resistance and tumor heterogeneity. The authors of the current study are careful to frame their findings as evidence that ormeloxifene restrains tumor progression by promoting irreversible senescence, and the irreversibility claim is central to that framing, since a senescent state that cannot be exited is far less likely to feed tumor regrowth than a transient one.

Technically, the study is a textbook example of how classical proteomics can still open doors in the era of genomics. Two-dimensional gel electrophoresis combined with MALDI-TOF/TOF mass spectrometry is labor-intensive and lower throughput than modern shotgun proteomics, but it excels at revealing shifts in protein abundance and isoforms in a visually interpretable format, and it allowed the team to detect the senescence signature before committing to targeted validation. The downstream validation cascade, spanning MTT assays, clonogenic survival, flow cytometry, dual senescence staining and Western blotting of cell-cycle regulators, follows the standard logic of discovery-driven cancer pharmacology: find the phenotype first, then confirm it with orthogonal methods.

For now, the work remains at the cell-culture stage, conducted in two breast cancer cell lines representing the two major clinical subtypes, hormone receptor-positive and triple-negative. The IC50 values in the low micromolar range are within the reach of achievable plasma concentrations for many oral agents, and the drug’s decades of human use as a contraceptive mean that its pharmacokinetics, dosing and safety in healthy women are already well characterized, potentially shortening the path to clinical evaluation considerably. The authors acknowledge support from the CSIR-National Laboratories Scheme and the DBT-BioCARe program, and the study was conducted at CSIR-CDRI, the institution where centchroman was originally developed. If the senescence mechanism holds up in animal models and combination studies with tamoxifen, a fifty-year-old contraceptive pill could find itself reborn as a senescence-inducing partner drug for breast cancers that have stopped responding to endocrine therapy, a repurposing story that few in the field would have predicted even a decade ago.

Subject of Research: Senescence induction by the selective estrogen receptor modulator ormeloxifene in breast cancer cells

Article Title: Ormeloxifene, a non-steroidal selective estrogen receptor modulator induces senescence in breast cancer cells

Article References: Singh, S., Srivastava, S., Siddiqui, S., Sharma, A., & Trivedi, A. K. (2026). Ormeloxifene, a non-steroidal selective estrogen receptor modulator induces senescence in breast cancer cells. Molecular Biology Reports, 53(1), Article 1665. https://doi.org/10.1007/s11033-026-12839-y

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12839-y

Keywords: ormeloxifene, centchroman, breast cancer, cellular senescence, tamoxifen, CDK4, CDK6, p21Cip1, p27Kip1, drug repurposing, proteomics, selective estrogen receptor modulator

DCIS, a non-invasive condition in which abnormal cells are confined to the milk ducts, accounts for roughly one in four breast cancers detected through screening programmes. Standard treatment options include mastectomy or breast-conserving surgery (BCS), with or without adjuvant radiotherapy, and in some cases endocrine therapy with drugs such as tamoxifen or aromatase inhibitors to reduce the risk of recurrence. Because approximately 65 to 80 percent of DCIS lesions are oestrogen receptor positive, knowing a tumour’s ER status is central to deciding whether hormone therapy is appropriate. Yet, as the new study demonstrates, ER testing for DCIS was performed in only 15.4 percent of the 5,813 women included in the cohort.

The researchers drew their data from the Breast Cancer Foundation National Register, which began collecting information in Auckland and Waikato in 2000, expanded to Christchurch in 2009 and Wellington in 2010, and achieved nationwide coverage only from 2020 onwards. By linking the register to New Zealand’s national Pharmaceutical Collection database through encrypted National Health Index numbers, the team could identify who was dispensed tamoxifen or aromatase inhibitors after a DCIS diagnosis. Statistical analyses employed multivariable logistic regression to identify factors associated with ER testing and cumulative incidence functions, with death treated as a competing risk, to estimate the probability of breast cancer events over time.

The headline finding is geographic. Of the 894 women who had an ER test on record, 65.6 percent were treated in the Waikato region, home to a well-established breast cancer research infrastructure and one of New Zealand’s two original breast screening pilot programmes. In Waikato, ER testing rose sharply from 35 percent in the late 1990s to 82.4 percent by 2003 and remained high, reaching 84.8 percent in 2022. Everywhere else, testing stayed stubbornly low, creeping from just 4.5 percent in 2000 to 7.1 percent in 2022. The investigators attribute Waikato’s exceptional performance to the participation of local clinical centres in international trials evaluating endocrine therapy for DCIS, including the UK/ANZ DCIS trial and the IBIS-II DCIS trial, which exposed clinicians there to the evidence base early and embedded testing into routine care.

The factors associated with receiving an ER test also differed dramatically by region, offering a window into contrasting models of care. In Waikato, women who received adjuvant radiotherapy after breast-conserving surgery were more likely to be tested, a pattern the authors interpret as reflecting local protocols that promoted both treatments in tandem rather than selective ordering by individual clinicians. Elsewhere in the country, testing appeared highly selective: older women, Māori women, those presenting with symptoms rather than through screening, and those with larger DCIS lesions exceeding 20 millimetres were more likely to be tested, suggesting clinicians ordered the test only when they believed the result would influence management. Nationally, the overall testing rate rose from 11.1 percent in 2000 to a peak of 23.3 percent in 2006 before drifting back down to 13.9 percent in 2022.

Among the 729 women whose DCIS was confirmed as ER positive, only 183, or 25.1 percent, actually initiated endocrine therapy, and more than 80 percent of those initiations occurred in Waikato. Tamoxifen was the most common first-line treatment, used by 58.5 percent of women starting therapy, followed by aromatase inhibitors at 38.3 percent. Consistent with shifts seen internationally after the NSABP B-35 trial suggested anastrozole outperformed tamoxifen in postmenopausal women, aromatase inhibitor use in Waikato climbed steadily, exceeding tamoxifen after 2018 and rising from 12.5 percent of initiations in the mid-2000s to 55 percent by 2022. Overall initiation of endocrine therapy in Waikato grew from 20 percent in 2000–2001 to 62.5 percent in 2022.

Does the hormone therapy actually help? After a median follow-up of 4.8 years, women with ER-positive DCIS who received endocrine therapy showed the lowest cumulative risk of any breast cancer event, but the differences between groups did not reach statistical significance, likely because the number of treated patients and events was simply too small to detect a benefit. The authors caution that these results do not exclude a clinically meaningful effect. Supporting evidence from prior research suggests that good adherence reduces recurrence, that at least two years of treatment decreases second breast events, and that adding endocrine therapy to breast-conserving surgery lowers the risk of subsequent invasive breast cancer compared with surgery alone. For a subset of Waikato women with documented therapy use of at least two years, the five-year cumulative incidence of a breast cancer event was just 6.3 percent, though this estimate rested on very few events.

The international context makes New Zealand’s numbers stand out even more sharply. In the United States, ER testing for DCIS surged from 17.5 percent in the early 2000s to 93.1 percent by 2012–2014, propelled by the 2000 approval of tamoxifen for DCIS following the NSABP B-24 trial. European testing rates range from 30 to 85 percent. Since 2020, both the ASCO/CAP guideline and the National Comprehensive Cancer Network have recommended ER testing for all DCIS patients to guide endocrine therapy decisions. New Zealand’s own early breast cancer guideline, last updated in 2009, recommends endocrine therapy for ER-positive invasive cancers but leaves the decision for ER-positive DCIS to individual circumstances, leaving clinicians without a clear national mandate for testing.

The study’s authors argue that the regional variation they documented is not an argument for exporting Waikato’s model wholesale, but rather evidence that nationally consistent guidelines and clinical pathways are urgently needed. Without standardised ER testing, they note, clinicians and patients cannot make informed decisions about whether the potential recurrence-reduction benefits of endocrine therapy, weighed against side effects such as aromatase inhibitor-related musculoskeletal symptoms, are worth pursuing in an individual case. Options such as low-dose tamoxifen, which showed comparable efficacy with improved tolerability in the TAM-01 trial, may widen the appeal of treatment for patients prioritising quality of life. Greater clinician participation in clinical trials, the researchers suggest, could simultaneously strengthen local evidence and keep practitioners engaged with emerging data.

Limitations temper some conclusions. Registry data capture began at different times in different regions, and nationwide coverage was achieved only in 2020, making endocrine therapy initiation numbers outside Waikato too sparse for trend analysis. Patient preferences regarding adjuvant therapy were unavailable, and the observed higher likelihood of testing among Māori women outside Waikato may reflect unmeasured local practice patterns rather than true differences in tumour biology. Nevertheless, as the first population-based study of ER testing and endocrine therapy for DCIS in New Zealand, the work delivers a clear message: a two-decade evidence gap persists in routine care, and closing it will require updated national guidelines, standardised receptor testing, and a broader culture of clinical research participation to ensure that women with DCIS everywhere benefit from treatments proven in trials.

Subject of Research: Oestrogen receptor testing and adjuvant endocrine therapy use in ductal carcinoma in situ in New Zealand

Article Title: Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study

Article References: Chen, Q., Campbell, I., Elwood, M., Cavadino, A., Aye, P. S., & Tin Tin, S. (2026). Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study. Breast Cancer Research and Treatment, 219(2), Article 6. https://doi.org/10.1007/s10549-026-08072-7

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08072-7

Keywords: ductal carcinoma in situ, oestrogen receptor testing, endocrine therapy, tamoxifen, aromatase inhibitors, breast cancer, New Zealand, regional variation, population-based study, clinical trials, recurrence, guidelines

The scientific motivation is stark. Breast cancer is the leading cause of cancer-related death in women worldwide, accounting for roughly 2.3 million new cases and nearly 685,000 deaths in 2020, about 30 percent of all cancers diagnosed in women. The burden falls especially hard in sub-Saharan Africa. In Cameroon alone, more than 4,000 new cases are recorded annually and over 2,000 women die of the disease. Standard treatments, including surgery, chemotherapy and hormone-blocking drugs such as tamoxifen, save lives but carry well-known liabilities: damage to healthy liver and kidney tissue, increased risk of secondary cancers, drug resistance, tumor recurrence and high costs. Against that backdrop, an estimated 80 percent of populations in Africa and Asia still rely on medicinal plants for primary health care, making rigorous scientific evaluation of those remedies a matter of both public health and drug discovery.

The research team, working with plant material harvested in Ngaoundere in Cameroon’s Adamawa region and authenticated at the National Herbarium of Cameroon, prepared two crude extracts from the tree’s stem bark: an aqueous extract made by soaking powdered bark in water for 24 hours, and a hydro-ethanolic extract using a 20 percent water, 80 percent ethanol mixture over 72 hours. Phytochemical profiling revealed a rich inventory of secondary metabolites in both preparations. Polyphenols dominated, at 348.78 milligrams of ascorbic acid equivalents per gram of dry weight in the aqueous extract and 434.22 in the ethanolic one, followed by flavonoids, tannins and flavonols. Consistent with this chemistry, both extracts showed potent free radical scavenging in the DPPH assay, with half-maximal inhibitory concentrations of roughly 19.7 and 17.2 micrograms per milliliter, and considerable ferric reducing power, confirming their capacity to neutralize the reactive oxygen species implicated in cancer initiation.

The in vitro results were striking. Tested against two human breast cancer cell lines, the estrogen-sensitive MCF-7 line and the aggressive triple-negative MDA-MB-231 line, both extracts inhibited growth in a dose-dependent manner within 24 hours. The ethanolic extract was the more potent, halting growth of MCF-7 cells at an IC50 of 41.63 micrograms per milliliter and MDA-MB-231 cells at 44.27, while the aqueous extract required 59.43 and 67.55 micrograms per milliliter respectively. Crucially, both extracts were far less toxic to non-cancerous human mammary epithelial cells, with IC50 values near 150 micrograms per milliliter, yielding a selectivity index above 2.5. That selectivity is the holy grail of cytotoxic drug development: a compound that kills cancer cells while sparing healthy ones.

Mechanistically, the extracts appear to work through two complementary routes. Flow cytometry showed that the aqueous extract pushed MCF-7 cells to accumulate in the DNA synthesis phase, raising the S-phase population from 15.75 percent in controls to 20.85 percent, while the ethanolic extract arrested cells at the G2/M checkpoint, increasing that population from 30.35 to 36.4 percent. Blocking the cell cycle at these points prevents mitotic entry and typically primes cells for apoptotic death. Fluorescence microscopy using acridine orange and propidium iodide co-staining confirmed that the aqueous extract triggered the morphological hallmarks of apoptosis, including membrane blebbing, chromatin condensation and the formation of apoptotic bodies, in both cancer cell lines. Apoptosis, or programmed cell death, is the preferred mechanism of cancer cell killing because, unlike necrosis, it minimizes inflammation and damage to surrounding tissue. Interestingly, neither extract significantly altered the cell cycle distribution of the triple-negative MDA-MB-231 cells, a reminder that the more aggressive molecular subtype may resist checkpoint regulation even as it succumbs to the extracts’ cytotoxic effects.

The decisive test came in living animals. The team induced mammary tumors in female Wistar rats using 7,12-dimethylbenz(a)anthracene, or DMBA, a polycyclic aromatic hydrocarbon carcinogen injected into the mammary region at 50 milligrams per kilogram of body weight. Every DMBA-exposed control rat developed tumors within the 140-day observation window, and two animals died. Rats treated daily by gavage with the aqueous bark extract at 75, 150 or 300 milligrams per kilogram fared dramatically better. Tumor incidence fell to 62.5 percent at the lowest dose and 25 percent at the middle dose, while tumor burden inhibition exceeded 85 percent at all doses, peaking at 99 percent at 150 milligrams per kilogram. Tamoxifen, the reference drug at 3.3 milligrams per kilogram, reduced tumor incidence to 37.5 percent and tumor burden by 44 percent. The extract also lowered tumor volume and slashed serum levels of CA15-3, a MUC-1-derived glycoprotein overexpressed in roughly 90 percent of breast cancers and widely used to monitor disease progression, to a degree comparable with tamoxifen.

Equally important was what the extract did to the biochemical environment that fuels tumor growth. DMBA exposure devastated the rats’ antioxidant defenses, elevating malondialdehyde, a marker of lipid peroxidation, while depleting glutathione and suppressing the activities of superoxide dismutase and catalase, the enzymes that detoxify superoxide anions and hydrogen peroxide. The bark extract reversed all of these changes, restoring redox homeostasis and protecting cell membranes from oxidative damage. It also tamed inflammation: DMBA raised serum levels of the pro-inflammatory cytokines TNF-alpha, IL-6, IFN-gamma and the angiogenic factor VEGF, all of which promote tumor progression and epithelial-to-mesenchymal transition through signaling pathways such as NF-kappaB and JNK. Treatment with the extract significantly reduced TNF-alpha, IL-6 and VEGF in a dose-dependent manner and boosted the anti-inflammatory cytokine IL-10 at the middle dose, suggesting it interferes with the inflammatory circuitry that enables tumors to grow, invade and recruit blood vessels.

Safety signals were reassuring across multiple fronts. Unlike tamoxifen, which caused progressive weight loss in treated rats consistent with its known anorectic effects, the extract produced no significant change in body weight over nearly five months of daily dosing. DMBA had elevated liver enzymes ALT and AST, alkaline phosphatase, bilirubin, urea and creatinine, hallmarks of hepatic and renal injury, and the extract normalized these markers in a dose-dependent fashion. Hematological analysis told a similar story: DMBA induced leukocytosis, anemia and elevated platelet counts, and the extract restored white blood cell, red blood cell, hematocrit and platelet values toward normal. Histology of the mammary glands showed that treated tumors lost their aggressive architecture, with only rare, loose tumor cell plaques persisting within necrotic areas at the highest dose. The authors note, however, that further work is needed to confirm activation of the intrinsic apoptotic pathway through caspase-9 and Bcl-2 family proteins, to characterize anti-estrogenic mechanisms directly, and to standardize the extract chromatographically with computational ADME modeling.

The study’s significance extends beyond a single plant. It demonstrates a rigorous pipeline, from traditional healer’s remedy to phytochemical characterization, selective cytotoxicity, mechanistic cell biology and long-term animal chemoprevention, that could be applied to the vast untested pharmacopoeia of African and Asian medicinal flora. If the polyphenol- and flavonoid-rich chemistry of Erythrina excelsa can be standardized, its active molecules isolated and its efficacy and safety confirmed in further preclinical and eventually clinical studies, a roadside tree of Cameroon may yet contribute a new, affordable and better-tolerated weapon against a disease that kills a woman somewhere in the world roughly every minute. For now, the message is one of validated promise: a remedy rooted in local knowledge has passed its first serious scientific examinations with remarkable results.

Subject of Research: Evaluation of the anti-breast cancer activity of Erythrina excelsa bark extracts in vitro and in vivo

Article Title: An In Vitro and In Vivo Assessment of the Anti‐Breast Cancer Activity of Erythrina excelsa Baker (Fabaceae) Bark Extracts

Article References: Walantini, J., Sipping, M. T. K., Ymele, M. N., Rebe, R. N., Yaya, J. A. G., Ndinteh, D. T., Njamen, D., & Zingue, S. (2026). An In Vitro and In Vivo Assessment of the Anti‐Breast Cancer Activity of Erythrina excelsa Baker (Fabaceae) Bark Extracts. Cancer Reports, 9(9), Article e70642. https://doi.org/10.1002/cnr2.70642

Image Credits: AI Generated

DOI: 10.1002/cnr2.70642

Keywords: breast cancer, Erythrina excelsa, chemoprevention, polyphenols, DMBA, apoptosis, antioxidants, tamoxifen, natural products, cell cycle arrest, CA15-3, ethnopharmacology